The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 21, 2020

Filed:

Dec. 20, 2016
Applicant:

Jiangsu Hengrui Medicine Co., Ltd., Lianyungang, Jiangsu, CN;

Inventors:

Guaili Wu, Jiangsu, CN;

Zhenjun Qiu, Jiangsu, CN;

Xi Lu, Jiangsu, CN;

Yun Lu, Jiangsu, CN;

Assignee:

Jiangsu Hengrui Medicine Co., Ltd., Lianyungang, Jiangsu, CN;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 487/04 (2006.01); A61P 35/00 (2006.01); A61P 37/00 (2006.01); A61P 37/02 (2006.01);
U.S. Cl.
CPC ...
C07D 487/04 (2013.01); A61P 35/00 (2018.01); A61P 37/00 (2018.01); A61P 37/02 (2018.01); C07B 2200/13 (2013.01);
Abstract

The present invention relates to a crystalline form of a BTK kinase inhibitor and the preparation method thereof. In particular, the present invention relates to a crystal form I of (R)-4-amino-1-(1-(but-2-ynoyl)pyrrolidin-3-yl)-3-(4-(2,6 -difluorophenoxy)phenyl)-1 H-pyrrolo[2,3-d]pyridazin-7(6H)-one (the compound of formula (I)) and the preparation method thereof. The crystal form I of the compound of formula (I) obtained by the present invention has a good crystalline stability and chemical stability, and the crystallization solvent used has a low toxicity and low residue, thus making it more suitable for use in clinical treatment.


Find Patent Forward Citations

Loading…